Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint diseaseLiliana F Mellor, Nuria Gago-Lopez, Latifa Bakiri, Felix N Schmidt, Björn Busse, Simon Rauber, Maria Jimenez, Diego Megías, Sergio Oterino-Sogo, Ricardo Sanchez-Prieto, Sergei Grivennikov, Xinzhu Pu, Julia Oxford, Andreas Ramming, Georg SchettSee the full list of authors
4 July 2022
Concise report: a minimal-invasive method to retrieve and identify entheseal tissue from psoriatic arthritis patientsMilena L Pachowsky, Maria Gabriella Raimondo, Cong Xu, Simon Rauber, Koray Tascilar, Hannah Labinsky, Mario Vogg, Mina Saad Aziz Saad, David Simon, Juergen Rech, Alina Soare, Lars Braeuer, Arnd Kleyer, Georg Schett, Andreas Ramming
22 April 2022
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposureAtul A Deodhar, Bernard Combe, Ana P Accioly, Rebecca Bolce, Danting Zhu, Amanda M Gellett, Aubrey Trevelin Sprabery, Gerd-Rüdiger R Burmester
7 April 2022
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio StudyLaure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatríz Joven-Ibáñez, Tatiana V Korotaeva, Frederic Lavie, Wim Noël, Michael T Nurmohamed, Petros P Sfikakis, Elke Theander, Josef S Smolen
24 February 2022
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritisPhilip J Mease, Atul A Deodhar, Désirée van der Heijde, Frank Behrens, Alan J Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee
3 March 2022
Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritisSayam Dubash, Oras A Alabas, Xabier Michelena, Leticia Garcia-Montoya, Richard J Wakefield, Philip S Helliwell, Paul Emery, Dennis G McGonagle, Ai Lyn Tan, Helena Marzo-Ortega
10 December 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trialAndrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Gabriela Alperovich, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Lisa Barcomb, Alan Kivitz
23 November 2021
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)Laura C Coates, Laure Gossec, Elke Theander, Paul Bergmans, Marlies Neuhold, Chetan S Karyekar, May Shawi, Wim Noël, Georg Schett, Iain B McInnes
24 November 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trialLars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Lisa Barcomb, Frank Behrens
15 December 2021
Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritisMaria Laura Acosta Felquer, Luciano LoGiudice, Maria Laura Galimberti, Javier Rosa, Luis Mazzuoccolo, Enrique R Soriano
19 July 2021
